Cardiovascular risk stratification is entering a new era of precision, and lipoprotein(a) sits at its center — yet this large randomized trial delivers a nuanced message that challenges the intuitive assumption that higher-risk patients always gain more from aggressive LDL-lowering therapy. For the millions of adults with elevated Lp(a) who have never had a heart attack or stroke, these findings reframe what that biomarker actually predicts.
The VESALIUS-CV trial enrolled 7,557 patients with established atherosclerosis or high-risk diabetes but no prior myocardial infarction or stroke, randomizing them to the PCSK9 inhibitor evolocumab or placebo over a median 4.6-year follow-up. Baseline Lp(a) was measured in all participants (median 28 nmol/L). Each 100 nmol/L increment in Lp(a) was independently associated with a 15% higher hazard of major coronary events overall, and a more pronounced 23% higher hazard specifically for myocardial infarction. Notably, no meaningful association emerged between Lp(a) and ischemic stroke risk in this cohort — a finding that diverges from some prior observational data. Critically, evolocumab's absolute and relative benefits did not scale with baseline Lp(a) level, suggesting the drug's mechanism — primarily LDL-C reduction via PCSK9 inhibition — operates independently of Lp(a) pathways.
This trial contributes meaningfully to an ongoing debate: because Lp(a) particles carry oxidized phospholipids and may promote inflammation and thrombosis through pathways distinct from LDL-C, PCSK9 inhibitors were never expected to be the ideal Lp(a)-targeting therapy. Evolocumab reduces Lp(a) modestly (roughly 20–25%), but that reduction appears insufficient to shift cardiovascular outcomes differentially by baseline Lp(a). The real clinical implication points toward emerging dedicated Lp(a)-lowering agents — RNA-based therapies like pelacarsen and olpasiran — currently in phase III trials. For the present, VESALIUS-CV reinforces Lp(a) as a legitimate independent risk marker in primary prevention-adjacent populations, while clarifying that PCSK9 inhibition addresses LDL-C risk rather than the Lp(a)-specific risk burden. Single-trial limitations and the pre-MI/stroke population restrict generalizability.